TG Therapeutics enters the final stretch of Q3 with an unusual split: the stock is holding near multi-year highs while short sellers are quietly rebuilding positions at a pace that puts short interest among the heaviest in the biotech sector.
Short interest has climbed steadily to 21% of the free float — around 30.7 million shares — up roughly 2.3% on the week and 3.1% over the past month. That is a persistent, grinding build rather than a sudden spike, suggesting this is conviction-driven positioning rather than opportunistic noise. The ORTEX short score has tracked higher in lockstep, reaching 75.0 on September 24, its highest reading in at least two weeks. Yet the borrow market tells a less alarming story for bulls: availability remains comfortable at 259%, well above the 52-week tightest level of 190%, and the cost to borrow has actually eased — dropping nearly 10% on the week to just 0.39%. There is no shortage of shares to borrow, and bears are not paying a premium for the privilege. Options positioning adds one more nuance: the put/call ratio at 0.41 barely budges above its 20-day average of 0.40, with a z-score under 1.0. Taken together, the positioning picture is one of elevated but orderly short conviction, not a market bracing for a sharp move.
The Street is broadly constructive but far from unified. Most active analysts carry Buy ratings, with JP Morgan raising its target to $72 in early August and HC Wainwright maintaining its $78 target as recently as September 1. B. Riley Securities holds the most aggressive bull case at $86, citing the commercial ramp of Briumvi. The outlier is Bank of America, which maintains an Underperform with a $20 target — a figure that looks anomalous against a $57 stock and a consensus mean target near $78, though BofA did raise that target from $17 in July, suggesting even the bear acknowledges upward momentum. The Briumvi bull case rests on a single-infusion dosing regimen that proponents argue will drive anti-CD20 market share gains and newly opened expansion into treatment-resistant schizophrenia via Phase 2. Bears counter that oral BTK inhibitors are closing the efficacy gap, and compliance risk around Briumvi's schedule could limit its ceiling against entrenched competitors. Valuation reflects the tension: the P/E sits near 23.7x, price-to-book at 16.8x — premium multiples that leave little room for a commercial miss. EPS momentum ranks in the 88th percentile over 30 days, yet the forward earnings picture and EPS surprise rank (11th percentile) point to a market still uncertain about how fast profitability scales.
Institutional flows add context without changing the picture dramatically. BlackRock holds 15.5% of shares and added modestly in the most recent period. State Street added 115,000 shares. D.E. Shaw more than tripled its position in Q2 to 3.4 million shares — a meaningful accumulation from a quant-leaning shop. Soleus Capital, on the other hand, trimmed by over 1.1 million shares in the same period. On the insider side, the only open-market trade in the past 90 days was Director Laurence Charney selling 5,000 shares on September 10 at $54.96 — a modest $275,000 transaction, not under a 10b5-1 plan, and worth noting but not alarming in isolation.
The last earnings print, on August 5, produced a tame 1.7% one-day move. The prior release — August 3 — fell 6.3% in a single session and held much of that loss over five days. The next event is scheduled for November 3, which gives shorts roughly five weeks to either press or cover. Most correlated peers had a difficult week: VYGR fell 13% and RNAC dropped nearly 8%, while TGTX ended roughly flat — a relative resilience worth noting given the sector headwinds.
The November 3 print is where the debate crystallises: the question is less whether Briumvi is growing and more whether the commercial trajectory justifies premium multiples against a short base that has spent six weeks adding to its position without meaningful capitulation.
See the live data behind this article on ORTEX.
Open TGTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
